10-Q: SANUWAVE Reports Strong Q3 Revenue Growth, Refinances Debt

Sentiment:

Quarterly Report 6 November 2025 4:52 PM

SANUWAVE Health, Inc. reported a significant increase in revenue and net income for the third quarter and nine months ended September 30, 2025, driven by UltraMIST sales and a strategic debt refinancing.

Capital raiseOn September 25, 2025, the Company entered into a new credit agreement (JPM Credit Agreement) with JPMorgan Chase Bank, N.A., providing a $23.0 million secured term loan and a $5.0 million secured revolving credit facility.The term loan has payments through September 25, 2029, and the revolving credit facility matures September 25, 2027.Loans accrue interest at SOFR plus 3.50% or CBFR plus 2.50%.The undrawn amount available under the revolver was $4.3 million as of September 30, 2025.Management explicitly states it will "continue to evaluate opportunities to further enhance our capital structure and support our growth strategy."

Better than expectedNet income for the three and nine months ended September 30, 2025, showed a significant positive swing from substantial losses in the prior year periods.Revenue growth of 22% for the quarter and 39% year-to-date demonstrates strong operational performance.Gross margin improved to 78% for both periods, indicating better pricing and cost management.The successful refinancing of debt and the alleviation of the 'going concern' doubt represent a major improvement in financial stability.The $5.0 million gain from the patent sale provided a significant one-time boost to income and cash flow.

Summary

Revenue for the three months ended September 30, 2025, increased by 22% to $11.5 million, up from $9.4 million in the same period of 2024.
Revenue for the nine months ended September 30, 2025, increased by 39% to $31.0 million, up from $22.3 million in the same period of 2024.
Net income for the three months ended September 30, 2025, was $10.3 million, a significant improvement from a net loss of $20.7 million in the prior year period.
Net income for the nine months ended September 30, 2025, was $5.7 million, compared to a net loss of $18.6 million in the prior year period.
Gross margin improved to 78% for both the three and nine months ended September 30, 2025, up from 76% and 74% respectively in the prior year periods.
Operating income for the nine months ended September 30, 2025, increased by 50% to $4.3 million, compared to $2.9 million in the same period of 2024.
Successfully refinanced outstanding debt on September 25, 2025, with a new $23.0 million secured term loan and a $5.0 million secured revolving credit facility, alleviating prior 'going concern' doubts.
Received a $5.0 million cash payment on August 21, 2025, from a patent purchase agreement, recognizing a gain on sale of patents.
Identified and continues to address material weaknesses in internal controls over key accounting and IT processes, including a lack of expertise for complex transactions.

Sentiment

Score: 8

Explanation: The Company has demonstrated a strong financial turnaround with significant revenue growth, a return to net profitability, and successful debt refinancing that alleviated going concern doubts. The patent sale also provided a substantial cash infusion. However, persistent material weaknesses in internal controls temper the overall positive sentiment.

Positives

Revenue increased by 22% to $11.5 million for the three months ended September 30, 2025, and by 39% to $31.0 million for the nine months ended September 30, 2025.
Achieved net income of $10.3 million for the three months and $5.7 million for the nine months ended September 30, 2025, a substantial turnaround from prior year losses.
Gross margin improved to 78% for both the three and nine months ended September 30, 2025, driven by improved pricing and decreased system costs.
Operating income for the nine months ended September 30, 2025, increased by 50% to $4.3 million.
Successfully refinanced principal debt obligations with JPMorgan Chase Bank, N.A., extending maturities and providing additional liquidity through a secured revolving credit facility.
Substantial doubt about the ability to continue as a going concern has been alleviated due to debt refinancing, achievement of operating income, and cash inflow from a patent purchase agreement.
Received a $5.0 million cash payment and recognized a gain on the sale of intravascular shockwave application patents.
Total Stockholders Deficit significantly improved from $(12.717) million at December 31, 2024, to $(2.931) million at September 30, 2025.

Negatives

Operating income for the three months ended September 30, 2025, decreased by 25% to $1.5 million, primarily due to increased non-cash stock-based compensation charges of $1.4 million.
General and administrative expenses increased significantly by 89% to $4.8 million for the three months and 65% to $13.3 million for the nine months ended September 30, 2025, largely due to stock-based compensation and increased headcount.
Disclosure controls and procedures and internal control over financial reporting were not operating effectively as of September 30, 2025, with material weaknesses identified.
Lacked internal controls over key accounting and IT processes, expertise for complex financial instruments and derivatives, and resources for financial instruments in service agreements.
An IRC Section 382 analysis showed that $44.2 million of net operating loss (NOL) tax attributes would expire before becoming available due to ownership shifts.

Risks

Material weaknesses in internal controls over financial reporting could lead to errors in financial statements, restatements, failure to meet reporting obligations, and loss of investor confidence.
Reliance on single suppliers for most product component materials could result in production disruptions if any of these suppliers are lost.
The outcome of legal matters is inherently unpredictable and subject to significant uncertainties, though no material adverse effects are currently anticipated.
The ability to utilize net operating loss carryforwards and certain other tax attributes may be limited due to ownership changes under IRC Section 382, with $44.2 million of NOLs expected to expire.

Future Outlook

Management believes the Company has sufficient resources to meet its obligations and continue operations for the foreseeable future, based on the successful debt refinancing, achievement of operating income, and cash inflow from the patent purchase agreement. The Company will continue to monitor its financial position, liquidity, and compliance with debt covenants, and evaluate opportunities to further enhance its capital structure and support its growth strategy.

Management Comments

"We continued to realize significant revenue growth during the three months ended September 30, 2025, as compared to the same period in 2024."
"management believes the Company has sufficient resources to meet its obligations as they become due and to continue its operations for the foreseeable future."
"Management remains focused on maintaining the Company's improved financial position and operational momentum."
"We are confident that the steps taken to date position the Company well to support ongoing operations and execute on our strategic objectives."

Industry Context

The filing indicates that the Company operates in one reportable segment, engaged in the design and sale of medical devices, primarily in the United States. It uses net income (loss) in competitive analysis by benchmarking to competitors, but does not provide specific details on broader industry trends or competitor performance.

Management Changes

Role	Previous Person	New Person	Effective Date	Reason
Former employee/officer	Nanci Gilmore	NA	2025-07-28	Separation and Release Agreement
Former employee/officer	Andrew Walko	NA	2025-10-24	Separation and Release Agreement

Corporate Governance

Change Type	Description	Effective Date	Impact Assessment
Internal Control Weaknesses	Identified material weaknesses in disclosure controls and procedures and internal control over financial reporting, including lack of controls over key accounting/IT processes, expertise for complex transactions, and internal resources for financial instruments.	2025-09-30	Requires significant management time and expense to remediate, with potential for errors in financial statements and loss of investor confidence if not addressed.
Equity Incentive Plan Amendment	An amendment to the 2024 Equity Incentive Plan was ratified, authorizing an additional 500,000 shares of common stock for issuance under the plan.	2025-08-19	Increases the pool of shares available for stock-based compensation, potentially impacting dilution and employee incentives.

Legal Proceedings

The Company is involved in various legal proceedings in the ordinary course of business but does not believe there are any pending matters that will have a material adverse effect on its business, financial position, results of operations, or cash flows.

Related Party Transactions

In June 2024, the Company entered into a $0.5 million promissory note with a related party, which was paid in full with accrued interest in October 2024.

Stakeholder Impact

Shareholders: Positive impact from improved financial performance, debt refinancing, and patent sale, but potential dilution from stock-based compensation and limitations on NOLs.
Employees: Increased headcount expenses and stock-based compensation indicate growth and incentive programs, but also note separation agreements for two individuals.
Creditors: The successful debt refinancing with JPMorgan Chase Bank, N.A. significantly improved the Company's credit profile and extended debt maturities.
Customers: Increased sales of UltraMIST disposables and systems suggest strong product demand and market acceptance.
Suppliers: Continued reliance on single suppliers for most product component materials poses a risk of disruption.

Next Steps

Continue to implement and enhance appropriate internal controls to remediate identified material weaknesses.
Hire additional personnel and segregate certain duties to strengthen control activities and mitigate risks.
Collaborate with an external vendor to enhance IT general controls over the enterprise resource planning system.
Monitor financial position, operating results, and compliance with debt covenants on an ongoing basis.
Evaluate opportunities to further enhance the capital structure and support growth strategy.

Key Dates

Date	Description
2020-08-06	Original maturity date of the Seller Note and a convertible promissory note payable, which were not repaid and went into default.
2020-08-31	Date of asset purchase agreement with Celularity to acquire UltraMIST assets and issuance of a promissory note to Celularity.
2022-08-31	Company entered into Securities Purchase Agreements for Future Advance Convertible Promissory Notes.
2022-11-03	Company entered into Securities Purchase Agreements for Future Advance Convertible Promissory Notes.
2023-05-31	Company entered into Securities Purchase Agreements for Future Advance Convertible Promissory Notes.
2023-12-31	Company entered into Securities Purchase Agreements for Future Advance Convertible Promissory Notes.
2024-01-31	Company entered into Securities Purchase Agreements for Future Advance Convertible Promissory Notes related to conversion of Asset-Backed Secured Promissory Notes.
2024-03-20	Filing date of the Company's Annual Report on Form 10-K for the year ended December 31, 2024.
2024-03-31	One-time payment of $2.5 million related to the Patent License recorded in other income.
2024-05-31	Company utilized its election to convert the May Notes into shares of common stock upon maturity.
2024-06-03	Company entered into Securities Purchase Agreements for Future Advance Convertible Promissory Notes and a $0.5 million promissory note with a related party.
2024-08-07	Stockholders approved the 2024 Equity Incentive Plan.
2024-09-30	End of the prior year's third fiscal quarter.
2024-10-18	Effective date of the one-for-three hundred seventy five (1:375) reverse stock split. All remaining outstanding convertible notes payable and convertible notes payable related party converted to 591,802 shares of common stock.
2024-12-03	Original maturity date of the $0.5 million promissory note with a related party.
2024-12-31	End of the prior fiscal year.
2025-03-27	Company entered into a new operating lease agreement for its new headquarters in Eden Prairie, Minnesota.
2025-03-28	Commencement date of the new operating lease for the headquarters.
2025-07-23	Licensee exercised the acquisition option for the patent portfolio.
2025-07-28	Date of Separation and Release Agreement between Nanci Gilmore and the Company.
2025-08-19	Amendment to the 2024 Equity Incentive Plan ratified, authorizing an additional 500,000 shares of common stock.
2025-08-21	Licensee made a $5.0 million cash payment to Sanuwave, Inc. for the patent purchase agreement.
2025-09-01	Monthly lease payments commenced for the new headquarters.
2025-09-25	Company entered into a new credit agreement (JPM Credit Agreement) and concurrently paid off and terminated the Existing Debt.
2025-09-30	End of the current reporting period.
2025-10-24	Date of Separation and Release Agreement between Andrew Walko and the Company.
2025-11-03	Date of common stock outstanding count (8,576,164 shares).
2025-11-06	Filing date of this Form 10-Q.
2025-12-31	Principal payments on the term loan will commence.
2026-09-01	Annual escalation of 3.5% for lease payments begins.
2027-09-25	Maturity date of the secured revolving credit facility.
2029-09-25	Maturity date of the secured term loan.
2030-08-30	Expiration date of the initial term for the new operating lease.

Recommendation

buy

The Company has demonstrated a remarkable turnaround, moving from significant losses and 'going concern' doubts to net profitability and a strengthened balance sheet. The successful debt refinancing and the substantial gain from the patent sale have significantly de-risked the Company's financial position. Strong revenue growth in UltraMIST products indicates solid market traction. While material weaknesses in internal controls are a concern, management has outlined a clear remediation plan. The overall trajectory suggests strong positive momentum and potential for continued growth, making it an attractive investment opportunity for a seasoned investor.

Keywords

SANUWAVE, SNWV, Quarterly Report, Medical Devices, Regenerative Medicine, UltraMIST, Shockwave Therapy, Financial Results, Debt Refinancing, Patent Sale, Internal Controls, Going Concern, Revenue Growth, Net Income

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.